And in the mechanistic study, using bioinformatics analysis, reporter assay, correlation analysis in clinical sample and loss or gain of functional experiments, we showed that RAD51 is a novel and bona fide target of miR-124 in GBM cells. This evidence concerns the gene RAD51 and glioblastoma.